Automate Your Wheel Strategy on MTSR
With Tiblio's Option Bot, you can configure your own wheel strategy including MTSR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MTSR
- Rev/Share 0.0
- Book/Share 4.2833
- PB 12.3375
- Debt/Equity 0.0024
- CurrentRatio 5.2594
- ROIC -0.5903
- MktCap 5551659694.0
- FreeCF/Share -1.6989
- PFCF -31.1579
- PE -18.0052
- Debt/Assets 0.0017
- DivYield 0
- ROE -0.8976
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MTSR | Wells Fargo | Overweight | Equal Weight | -- | $54 | Sept. 30, 2025 |
| Initiation | MTSR | Leerink Partners | -- | Outperform | -- | $77 | Sept. 9, 2025 |
| Initiation | MTSR | Wells Fargo | -- | Overweight | -- | $65 | June 20, 2025 |
| Initiation | MTSR | BofA Securities | -- | Buy | -- | $38 | Feb. 25, 2025 |
| Initiation | MTSR | Evercore ISI | -- | Outperform | -- | -- | Feb. 25, 2025 |
| Initiation | MTSR | Guggenheim | -- | Buy | -- | $56 | Feb. 25, 2025 |
News
Healthy Returns: Pfizer's new obesity bet, Metsera, releases encouraging data on lead drug
Published: September 30, 2025 by: CNBC
Sentiment: Positive
Metsera released data from mid-stage trials on its lead obesity drug candidate, while a high stakes Medicare open enrollment approaches.
Read More
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer.
Published: September 30, 2025 by: Barrons
Sentiment: Positive
Pfizer said last week it would pay $47.50 per share for Metsera, and an extra $22.50 per share if its drugs hit certain milestones.
Read More
Pfizer's Metsera buy raises competitive heat for Novo Nordisk
Published: September 23, 2025 by: Proactive Investors
Sentiment: Negative
UBS has warned that Pfizer Inc's (NYSE:PFE, ETR:PFE) $7.3 billion acquisition of Metsera will sharpen competition for Novo Nordisk (NYSE:NVO) in the fast-growing obesity drug market, particularly towards the end of the decade. The bank kept its 'neutral' rating on Novo shares with a DKr340 price target, implying 12.5% downside from the current level.
Read More
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Published: September 22, 2025 by: Fast Company
Sentiment: Positive
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications for obesity and cardiometabolic diseases, in a deal valued at as much as $7.3 billion.
Read More
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ODP and MTSR on Behalf of Shareholders
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Sept. 22, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: ODP Corporation (NASDAQ: ODP)'s sale to an affiliate of Atlas Holdings for $28.00 per share in cash.
Read More
Pfizer Stock Higher on Multi-Billion Dollar Metsera Buyout
Published: September 22, 2025 by: Schaeffers Research
Sentiment: Positive
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Read More
Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders
Published: September 22, 2025 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE , Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.
Read More
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
Published: September 22, 2025 by: Proactive Investors
Sentiment: Positive
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in cash. Metsera is also eligible to receive an additional $22.50 per share contingent on the achievement of certain performance milestones.
Read More
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
Published: September 22, 2025 by: Investopedia
Sentiment: Positive
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares of Pfizer were up slightly.
Read More
Recent Price Trend in Metsera Inc. (MTSR) is Your Friend, Here's Why
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
If you are looking for stocks that are well positioned to maintain their recent uptrend, Metsera Inc. (MTSR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Read More
Wall Street Analysts See a 55.72% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Metsera Inc. (MTSR) points to a 55.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Metsera Inc. (MTSR) Is a Great Choice for 'Trend' Investors, Here's Why
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Metsera Inc. (MTSR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 89.7% in Metsera Inc. (MTSR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial
Published: June 09, 2025 by: Reuters
Sentiment: Positive
Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for a monthly dosing regime.
Read More
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations
Read More
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025
Read More
Metsera to Present at TD Cowen's 45th Annual Health Care Conference
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, from 1:10 – 1:40 p.m. ET.
Read More
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing and a strong safety profile. Positive phase 2a results for MET-097i showed significant mean placebo-adjusted weight loss up to 11.3% without plateau after 12 weeks, with phase 2b and monthly dosing data expected in 2025. MET-233i, a long-acting amylin analog being explored in a phase 1 study, is expected to have a data release in mid-2025.
Read More
About Metsera, Inc. (MTSR)
- IPO Date 2025-01-31
- Website https://metsera.com
- Industry Biotechnology
- CEO Christopher Whitten Bernard
- Employees 93